State AGs Say Gilead Shouldn't Have Exclusive Right To Costly Remdesivir Treatment Gilead's remdesivir is the only drug granted emergency use authorization from the FDA to combat Covid-19 after showing positive results in clinical trials, but the company received criticism by pricing a treatment course at $3,120 for patients with private insurance.